Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Ineffective medication can remove the "worst fear" of schizophrenia.

2.

How access to specialized cancer centers affects glioblastoma outcomes

3.

Data indicate 1 in 3 US adults unaware of connection between HPV and cancers

4.

Since 2000, the outlook for multiple myeloma has improved.

5.

Characterizing metastatic disease during adaptive therapy by using dynamic biomarkers and mathematical modeling.


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot